AGENUS going back in
Agenus 
AGEN is a stock that I have not followed since they were forced (unfairly) by the FDA to pull their NDA for balstilimab. However recently price action has started to look favourable and this is in conjuction with ASCO where the company is presenting clinical data from 2 trials.
AGEN is a stock that I have not followed since they were forced (unfairly) by the FDA to pull their NDA for balstilimab. However recently price action has started to look favourable and this is in conjuction with ASCO where the company is presenting clinical data from 2 trials. 
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。